The Radiopharmaceutical Infrastructure Playbook: Why Telix's FDA Approval for Pixclara Redefines Neuro-Oncology Diagnostics and Theranostics
Dr. Dereck Mush, MD, MBAKevin Richardson
CEO, Telix Precision Medicine, Telix Pharmaceuticals
- Industry
- Precision oncology and radiopharmaceuticals
- Based in
- Indianapolis, USA
- Company funding
- Undisclosed
- Region
- North America
Healthcare executive with more than 25 years of industry experience, including radiopharmaceutical commercial operations.
Leads Telix Precision Medicine, including diagnostics, global marketing, and commercial operations in the United States and Canada.
Kevin Richardson is CEO of Telix Precision Medicine.
More founders in Precision oncology and radiopharmaceuticals
- Dr. Christian Behrenbruch
Telix Pharmaceuticals
Related on The Signal
Dr. Dereck Mush, MD, MBA
Inside TumorSight Risk: What MRI-Based Recurrence Assessment Can and Cannot Tell Clinicians
Dr. Dereck Mush, MD, MBA
The Post-REMS Long-Acting Psychiatric Revolution: How Subcutaneous Copolymer Delivery Unlocks Olanzapine Outpatient Economics
Dr. Dereck Mush, MD, MBA
Inside SimBioSys TumorSight Risk: Bringing Recurrence Assessment Into the MRI Workflow
Dr. Dereck Mush, MD, MBAKeep exploring